WINNIPEG, MANITOBA -- (MARKET WIRE) -- November 06, 2006 -- Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce that it has begun the validation study for its gastric cancer biomarkers.
